Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research [EARLY_Phase 1]
This early-phase (Phase 1) clinical trial investigates the safety and preliminary efficacy of Meta10-19 metabolically armed CD19 CAR-T cells…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]
This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refracto…
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation [Phase 1]
Phase 1 trial evaluating Zanubrutinib in combination with Odronextamab for Richter transformation in transformed chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial evaluating a combination of homoharringtonine, a BCL-2 inhibitor, rituximab, and prednison…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]
Phase I study to establish safety and maximum tolerated dose of autologous BCMA-targeting CAR T-cells in relapsed/refractory diffuse large B…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL [Phase 1, Phase 2]
An early-phase Phase I/II trial evaluating TRS005 in combination with T-CHP (cyclophosphamide, doxorubicin, prednisone) for previously untre…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating Orelabrutinib in combination with the Polatuzumab vedotin-containing Pola-R-CHP regimen for untreated non-GCB diffu…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Pola-ZR2P in Previously Untreated DLBCL [Phase 2]
This clinical trial update reports a Phase 2 study of Pola-ZR2P for previously untreated diffuse large B-cell lymphoma, currently recruiting…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders [Phase 1]
Phase 1 trial update for Epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorders, including DLBCL-type PTLD and …
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma [Phase 2]
A Phase 2 trial is evaluating the efficacy of epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma, employing a…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas [Phase 1]
Phase 1 feasibility trial evaluating the combination of tazemetostat with CAR T-cell therapy in B-cell lymphomas, including follicular lymph…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating HDM2005 in combination with standard of care for diffuse large B-cell lymphoma is currently recruiting…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: G-Pola-ZLP in Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial update indicates the G-Pola-ZLP regimen for Diffuse Large B-Cell Lymphoma is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL [Phase 1, Phase 2]
A phase 1/2 study evaluating GFH009 in combination with zanubrutinib for relapsed or refractory diffuse large B-cell lymphoma is currently r…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 clinical trial evaluating Brentuximab Vedotin plus Rituximab with dose-attenuated CHP in elderly patients with diffuse large B-cel…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab plus ICE chemotherapy for refractory or recurrent CD20-positive mature non-Hodgkin lymphoma i…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 clinical trial is evaluating acalabrutinib in combination with R-CHOP for previously untreated diffuse large B-cell lymphoma and i…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1]
A Phase 1 trial is evaluating adding loncastuximab and roflumilast to the Rituximab-CHOP regimen for adults with naïve high-risk Diffuse Lar…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: Prospective Observational Study of Diffuse Large-cell B Lymphoma
This is an ongoing prospective observational study of diffuse large B-cell lymphoma that is currently recruiting. The sponsor is Grand Hôpit…
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies [Phase 1, Phase 2]
This document outlines a Phase I/II clinical trial of ALETA-001 for various B-cell lymphomas, with recruitment ongoing and sponsored by Canc…